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A. Carter,1 N.J. Turner1,2 and M.G. Walker1,2*Department of 1Vascular Surgery, Manchester Royal Infirmary, and 2UK Centre for Tissue Engineering,
University of Manchester, Oxford Road, Manchester, UKObjectives. To characterise the histological and cytokinetic characteristics of purely ischaemic ulcers and the processes that
underpin healing following successful revascularisation.
Design. Prospective observational study.
Materials and methods. Biopsies were taken immediately pre- and 6 weeks following successful revascularisation of solely
ischaemic ulceration. They were evaluated for morphological differences using H&E staining for the platelet derived growth
factor receptor (PDGFR), epidermal growth factor receptor (EGFR), TGFbreceptorIII (TGFbRIII), transforming growth
factor beta 1 and 3 (TGFb1 and TGFb3) and von Willebrand factor (vWF) expression using immunohistochemistry.
Localisation and quantification of these growth factors and receptors was assessed systematically by three independent
investigators who were blinded to the timing of biopsy.
Results. Pre-operatively, small vessel vasculitis, necrosis and infection with a profuse neutrophil and macrophage infiltrate
was observed in all samples. Post-operative biopsies revealed a proliferation of new capillaries in and around the ulcer edge
and base. vWF staining confirmed an endothelial layer within these new vessels. Following successful revascularisation
there was less infection and inflammation with minimal vasculitis. These newly formed capillaries had increased staining for
TGFb3, PDGFR and TGFbRIII with staining for PDGFR also localised to dermal fibroblasts which were larger and more
numerous. Accelerated epithelial cell proliferation was observed with detachment from the underlying dermis.
Conclusions. Healing of purely ischaemic ulcers is characterised by vasculogenesis associated with increased presence of the
proangiogenic cytokines PDGF and TGFb3. These findings show promise for the use of growth factor manipulation to aid
healing in ischaemic ulcers.Keywords: Ischaemic ulceration; Angiogenesis; Healing; Revascularisation.Introduction
In the pre-antibiotic era, numerous techniques were
developed to aid healing because of the potential life
threatening nature of open wounds and the problems
attendant to infection. Metchnikoff in his studies of
injured tissue, and the immune response evoked,
described the migration of microphages (neutrophils)
and macrophages to the site of injury.1 More than 100
years later we now believe these events to be crucial to
the regulation of the healing response, particularly in
the setting of limb ulceration.as presented in the ESVS Prize session at the ESVS
sinki, 2005.
ing author. Prof M.G. Walker, MCh, FRCS, Department
Surgery, Manchester Royal Infirmary, Oxford Road,
13 9WL, UK.
: stephanie.dalton@cmmc.nhs.uk
0516+ 07 $35.00/0 q 2005 Elsevier Ltd. All rights reserThe primary function of skin is to prevent the entry
of bacteria and viruses and to maintain internal
homeostasis in the face of injury. This barrier function
is provided by the external layer of keratinocytes
which form the epidermis, but is also reliant on the
tensile strength and elasticity provided by the
underlying dermis with its abundant matrix of
collagen and elastin fibrils. However, this barrier
function can be disrupted through either localised
damage in isolation or combined with poor tissue
perfusion seen in peripheral vascular disease.
Peripheral vascular disease (PVD) contributes to
20% of lower limb ulcers and is present in isolation in
about 10% of cases.2 Recent epidemiological studies
have shown that approximately 5% of males over 50
years suffer with intermittent claudication (IC) with
up to 25% of this group developing critical limb
ischaemia (CLI).3 Treatment of ischaemic ulcerationEur J Vasc Endovasc Surg 31, 516–522 (2006)
doi:10.1016/j.ejvs.2005.12.002, available online at http://www.sciencedirect.com onved.
Healing of Revascularised Ischaemic Ulceration 517poses a therapeutic challenge, usually due to local
injury in the setting of poor peripheral perfusion
combined with consequent failure of the ischaemic
epidermis to heal. Treatment for these patients
presents a challenge often necessitating revascularisa-
tion to achieve healing,4–7 whether by interventional
radiology, arterial surgery or a combination. These
treatments are fraught with significant morbidity and
mortality and long-term success is not always assured.
In patients with CLI there is a 10% early mortality rate
with a further 15% requiring major amputation by 1
year.8 Aortoiliac and femoro-popliteal disease are
amenable to revascularisation in the majority of cases
with excellent rates of limb salvage and ulcer healing.8
Small vessel disease, usually as a consequence of
diabetes mellitus or chronic renal impairment, is less
amenable to intervention and has much lower rates of
limb salvage and ulcer healing.8
Following epidermal disruption the process of
healing is dependant on an appropriate cellular
reaction mediated by cytokines and growth factors,
which regulate migration, proliferation, differen-
tiation and metabolism of cells. They act in a
paracrine manner on adjacent cells, as autocrine
factors on the secreting cell and as endocrine factors
bound to carrier proteins. Many such factors have
been identified as playing a key role in regulating
healing.
Amongst the most important growth factors impli-
cated in cutaneous healing in the setting of ischaemia
are platelet derived growth factor (PDGF),9 epidermal
growth factor (EGF),10 and transforming growth factor
beta 1 and 3 (TGFb1 and TGFb3).11 The processes
underlying healing and failure to heal in chronic
venous or neuro-ischaemic ulceration have been
extensively studied.12–16 Indeed numerous published
trials, largely limited to chronic venous or neuro-
ischaemic ulceration, have sought to improve healing
through manipulation of the local environment with
local or parenteral administration of growthTable 1. Patient demographics
Patient no. Sex Age Affected limb Site of ulc
1 M 42 L Ankle
2 F 72 L Ankle
3 F 85 L Heel/ank
4 M 46 R Ankle
5 M 67 R Ankle
6 M 49 R Heel/ank
7 F 62 L Heel/ank
8 M 74 R Ankle
Mean 62.1
IHD, ischaemic heart disease; L, left; R, right; M, male; F, female.factors.17,18 However, knowledge of the complex
pathologies involved in chronic limb ischaemia and
the healing processes that follow successful revascu-
larisation is limited.Aims
This study seeks to describe the early changes in the
dermal structure, expression of growth factors and
associated growth factor receptors (GFR) in chronic
lower limb ischaemic ulcers immediately prior to and
following successful bypass surgery. We also seek to
correlate these changes in dermal and epidermal
architecture of healing ulcers with changes in the
cytokinetic milieu.Methods
Committee approval for the study was given by the
Ethics Committee of the Central Manchester Health-
care Trust. Non-diabetic patients with purely ischae-
mic ulceration, defined as lower limb epidermal defect
of greater than 1 month duration with an ABPI of!0.8
that had failed to respond to conservative treatment,
were recruited to the study. Inclusion criteria included
angiographic evidence of femoro-popliteal disease
suitable for reconstruction, without significant small
vessel disease or calcification. Patients with clinically
neuro-ischaemic ulcers, coexistent venous disease
identified on duplex scanning, evidence of osteomyel-
itis and patients without macroscopic evidence of
healing at 6 weeks were excluded. Patient demo-
graphics are summarised in Table 1.
Eight patients fulfilled the criteria for the studywith
a mean age of 62.1 years (42–85 years). All patients had
evidence of femoro-popliteal disease with at least two
patent infra-crural vessels. All patients had punch
biopsy to include ulcer base, edge and surrounding
skin immediately prior to surgery. Two patients hader Ulcer size (cm) Hypertension Smoker IHD
3 Y Y N
2 Y Y Y
le 3 Y Y Y
3 N Y Y
2 N Y Y
le 6 Y Y Y
le 4 Y N N
6 Y Y Y
3.6
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Table 2. Histology mean scores
Surrounding skin Ulcer edge Ulcer base
Pre Post Pre Post Pre Post
Infection 3.3 1.3 4.0 1.7 4.7 2.0
Acute inflammation 3.3 1.0 4.0 0.7 3.3 1.3
Chronic inflammation 2.3 2.0 3.3 3.0 3.7 3.0
Necrosis 0.0 0.0 2.3 0.0 3.7 0.3
Fibroblast number 3.3 4.7* 2.7 4.7 2.3 4.0
Angiogenesis 0.0 3.3 0.0 2.7 0.0 4.7
Vasculitis 2.7* 0.7 3.3 1.0* 1.8 1.3
The above table shows the mean scores out of five for morphological features before and after successful revascularisation.
* Scores where there was an inter-observer variation and a consensus opinion reached.
M. O. Murphy et al.518coexistent aorto-iliac disease and were treated with
pre-operative iliac angioplasty in both cases. Five men
and three women underwent femoro-popliteal or
infra-crural bypass with a mean pre-operative ulcer
diameter of 3.6 cm (2–6 cm). Patients were reviewed
at 6 weeks following successful revascularisation.
Following confirmation of macroscopic healing and
increased ABPI, the ulcer edge was re-biopsied, as
above, under local anaesthetic.Tissue preparation
Biopsies were immediately frozen in liquid nitrogen
and 5 mm sections cut onto poly-L-lysine coated slides
(Fisher Scientific, USA). Sections were stained using
Haematoxylin and Eosin (Raymond Lamb, UK) for
morphological analysis. Additional sections under-
went immunohistochemical staining for the growth
factors: TGFb1, TGFb3 and growth factor receptors:
EGF receptor (EGFR), TGFbreceptorIII (TGFbRIII),
PDGF receptor (PDGFR), all supplied by R&D
systems. In the case of PDGFR and EGFR, the receptor
antibodies were chosen due to technical difficulty
staining for their respective GF. Finally, sections were
stained for von Willebrand factor (vWF) to visualise
vascular endothelium.
For GF and GFR visualisation, a three-stage staining
procedure was employed. Briefly, endogenous peroxi-
dase activity was quenched with 3% (v/v) hydrogen
peroxide and the slides blocked in 10% (w/v) bovine
serum albumin (BSA) in phosphate buffer saline (PBS)
for 1 h. All primary antibodies were used at 1:200
dilution and applied for 1 h at room temperature
(R&D catalogue nos. AF-236, AF-101-NA, AF-243-NA,
AF-914, AF-242-PB). The slides were washed for
30 min in PBS and a horse radish peroxidase
conjugated secondary antibody applied for a further
hour. The slides were developed using an avidin–
biotin complex (ABC kit, Vector Laboratories) for 30
min and visualised using a digital camera (Olympus
C-8080, Olympus UK Ltd). For vWF staining a similarEur J Vasc Endovasc Surg Vol 31, May 2006protocol was followed except fluorescein isothiocya-
nate (FITC) conjugated secondary antibody was used
to visualise the primary antibody (R&D, antibody ref
AF-385). Slides were visualised using a confocal
microscope (Leica SP2, Leica Microsystems Ltd, UK).
In both cases, control slides were made by omitting the
primary antibody.
Each sample was examined by three independent
investigators who were blinded to the timing of the
biopsy. Each section was divided into three zones:
surrounding skin, ulcer edge and ulcer base. Each
zone was further subdivided into: epithelium (sur-
rounding skin only), papillary dermis and reticular
dermis. A standardised scoring system was used for
H&E and GF/GFR stained sections. H&E sections
were scored on a scale of one to five for the presence of
predetermined features in each ulcer (Table 2). A
separate proforma was used to detect GF and GFR
staining in each ulcer zone. Pooled data was analysed
for post-operative alterations GF and GFR staining
and architectural changes. The number of micro-
vessels per 10! magnification field in each ulcer
zone was counted from vWF stained sections. When
there was a sizable inter observer variation, as was the
case in only three results, a consensus opinion was
reached among the investigators.Statistical analysis
Data are presented as mean with standard deviation of
each score. Student’s t-test was employed to determine
differences between pre- and post-operative data sets
with a P-value equal or less than 0.05 considered
significant.Results
The pre-operative ABPI of the ulcerated limb was !
0.7 in all patients. Revascularisation was successful in
all patients with a median ABPI increase from 0.5
Table 3. Operative details
Patient
no.
ABPI Angiography Operation
Pre-op Post-op
1 0.7 1.1 AI and SFA to 2 AI plasty and
FEM AK POP
(RSV)
2 0.1 0.4 SFA and POP to 2 FEM BK POP
(RSV)
3 0.0 0.9 SFA and POP to 2 Redo FEM
distal (RSV)
4 0.5 1.0 POP OCC to 2 FEM BK POP
and toe AMP
(RSV)
5 0.7 1.0 SFA to 2 FEM distalC
debride (RSV)
6 0.4 0.9 SFA and POP to 2 FEM BK POP
(RSV)
7 0.4 1.3 DIST SFA OCC to 2 FEM AK DIST
(PTFE)
8 0.7 0.9 SFA OCC to 2 FEM AK POP
(PTFE)
Mean 0.5 1.0
ABPI, ankle brachial pressure index; AI, aortoiliac; SFA, superficial
femoral artery; FEM, femoral; POP, popliteal; AK, above knee; BK,
below knee; DIST, distal; OCC, occlusion; 2, 2 vessel run-off; RSV,
reversed saphenous vein; AMP, amputation.
Healing of Revascularised Ischaemic Ulceration 519(0.0–0.7) to 1.0 (0.4–1.3) and macroscopic evidence of
ulcer healing at 6 weeks. Operative data are summar-
ised in Table 3. All the biopsy sites within the ulcers
healed without complication.Light microscopy H&E staining
Pre-operatively, a prominent inflammatory infiltrate
was present in most wounds, often extending into the
surrounding dermis. There was evidence of acute and
chronic inflammatory cells in all three zones of all
samples with attendant bacterial infection. In addition,
the ulcer bases exhibited areas of necrosis with small
vessel vasculitis in the surrounding skin edge in most
samples (Fig. 1(a)). It was noteworthy that the
epidermal edges grew downwards into the dermis
rather than across the surface.
Post-operatively, there was a marked reduction in
acute inflammatory cells within all zones though a
residual chronic inflammatory infiltrate remained
(PZ0.003). This was characterised by moderate
numbers of macrophages and small numbers of
neutrophils, in the absence of overt infection. There
were newly developed small blood vessels within the
deep and superficial dermis in all post-operative
sections, most notably at the ulcer edge and base
(Fig. 1(b)–(d)), confirmed by vWF immunofluores-
cence (Fig. 1(e)).In marked contrast to pre-operative biopsies, in
the post-operative biopsies the epidermis was
proliferating across the surface of the ulcer rather
than into the dermis. There was consistent reduction
in the degree of necrosis and vasculitis seen in and
around the ulcers following revascularisation
(PZ0.006).Growth factor staining
There was a paucity of staining for TGFb3 in the pre-
operative sections but a marked increase post-opera-
tively in and around the areas of neovascularisation
within the dermis of the healing ulcers (Fig. 1(b)).
TGFb3 immunostaining was observed throughout the
healing epidermis and fibroblasts in the surrounding
skin.
Immunohistochemical staining of surrounding skin
revealed the presence of TGFb1 particularly through-
out the epidermis and within dermal fibroblasts. There
was little change from pre-operative slides with a
small increase in staining localised to the dermal
fibroblasts. In contrast to TGFb3, there was little
staining for TGFb1 around the new blood vessels
following revascularisation. At the margins of the
ulcers, there was obvious TGFb1 staining in the
epidermis, the epithelium of hair follicles, and
fibroblasts. In addition, TGFb1 expression in the
epidermal margin of the ulcers was reduced compared
to that seen in normal surrounding epidermis. In the
healing ulcers minimal staining for TGFb1 was
observed.Staining for growth factor receptors
Pre-operative staining for PDGFR was confined to
inflammatory cells, vascular smooth muscle cells
(VSMC) and fibroblasts. Following revascularisation
the PDGFR was again localising to macrophages and
dermal fibroblasts but the latter were larger and more
numerable (PZ0.012). In addition, there was avid
staining for PDGFR in the areas of new blood vessel
formation (Fig. 1(c)).
There also was marked increased staining for
TGFbRIII around the areas of post-operative angio-
genesis and to a lesser extent dermal fibroblasts
(Fig. 1(d)).
There was minimal change for the epidermal
growth factor receptor (EGFR) from pre- to post-
operative samples and the staining was confined
mainly to the basal layer of the epidermis.Eur J Vasc Endovasc Surg Vol 31, May 2006
Fig. 1. (a) Pre-operative H&E. Ulcer base necrosis (asterix) with inflammatory cells and infection particularly at the ulcer edge
(arrow). (b) Post-operative TGFb3 immunohistochemistry. Staining of epidermis, fibroblasts and areas of dermal
vasculogenesis (asterix). (c) Post-operative PDGFR immunohistochemistry. Staining of new blood vessels (asterix) with
larger and more numerable fibroblasts within the deep dermis (arrow). (d) Post-operative TGFbRIII immunohistochemistry.
Localised to areas of vasculogenesis. (e) Post-operative vWF immunofluorescence. Demonstrates the endothelial lining of
lumen (green) of area of vasculogenesis (blue).
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Revascularisation has been the gold standard treat-
ment for non-healing ischaemic ulcers for almost 50
years, yet little is known of the mechanisms by which
revascularised ischaemic ulcers re-epithelialise. This
gap in knowledge is surprising but perhaps relates to
the difficulty in getting histological samples in this
setting. This is the first study of the processes by which
these ulcers heal following revascularisation.
Most studies of lower limb ulceration are popu-
lation, rather than aetiology based and so are a
reflection of an unselected patient group of ischaemic,
neuro-ischaemic and mixed ulceration. In this study,
we examine the histological changes that underpin
healing ischaemic ulceration. It is known that purely
ischaemic ulcers, even with only moderately impaired
ABPI of 0.9 fail to heal in 70% of cases.7
The biopsies showed prominent areas of angiogen-
esis within the dermis of the ulcer base in all cases.
Although angiogenesis is commonly seen within the
granulation tissue at the edge of healing wounds, the
larger dermal capillaries within the ulcer base seen in
this study are an unexpected finding. The formation of
true new blood vessels or angiogenesis and the
development of collateral vessels from pre-existing
blood vessels or atherogenesis are both important
processes in the pathophysiology of peripheral vas-
cular disease.19 Following injury and haemostasis,
hypoxia, high lactate levels and acidosis, stimulate
angiogenesis. Under the influence factors such as
bFGF and VEGF, endothelial cells proliferate and form
capillary buds. These cells secrete matrix metallopro-
teases which allow the vascular buds composed of
endothelial cells and SMC to dissect through the
wound matrix, while EGF and PDGF recruit pericytes
which stabilise the new vessel formation.20
Manipulation of these processes has been an
attractive therapeutic target for over a decade and
the subject of extensive investigation in cardiovascu-
lar, oncological and neurological research. Topical and
systemic delivery of both vascular endothelial cell
growth factor (VEGF) and basic fibroblast growth
factor (bFGF) have been used in the setting of end
stage coronary ischaemia21–24 and PVD25,26 in the hope
of alleviating ischaemic symptoms. It was widely held
that these factors were deficient in arterial ulcers,
hence their use in therapeutic angiogenesis. However,
more recent studies have questionedwhether there is a
true deficiency of bFGF and VEGF in this setting,27,28
providing a possible explanation for the poor efficacy
of these potent angiogenic factors in randomised
control trials.21–24 In addition, concerns abound
about the deleterious effects of pro-angiogenic factorsin vascular patients with occult malignancies, pro-
liferative retinal disease and unstable atherosclerotic
plaques22 common in an elderly arteriopathic patient
group. Perhaps a less potent but more physiological
approach is warranted.
Because of histological evidence of angiogenesis we
then looked at the expression and localisation of
proangiogenic cytokines. VEGF and bFGF have been
extensively studied in ischaemia but because of their
failure to impact on healing rates in randomised
control trials some have questioned their importance.
We, therefore, chose to further examine the tissue
samples for other pro-angiogenic ligands namely
PDGF and the TGFb superfamily, in particular TGFb3.
In the healing ischaemic ulcers we found minimal
staining for TGFb1. This contrasts with healing in
normal dermal wounds where the addition of
exogenous TGFb1 to existing native TFGb1 and ligand
receptors enhances the repair process through
increased cellularity, keratinocyte migration and
collagen deposition.29 Based on our work it is more
likely that TGFb3 would stimulate the angiogenic
processes that seems essential to the type of healing we
observed in ischaemic tissue. It is noteworthy that this
GF has shown efficacy in human skin trials as an anti-
scarring agent, reportedly by simulating the healing
that occurs in uterowhere higher levels of TGFb3 occur
than in adult healing. It is possible that TGFb3 may be
responsible for regeneration rather than repair and so
would seem a promising adjunct to healing in
ischaemic ulceration. TGFbRIII is predominantly
expressed on endothelial cells and binds TGFb1 and
TGFb3 but not TGFb2. TGFbRIII is upregulated in
tumour associated vasculogenesis and so has been
proposed as a target for anti-angiogenic therapy in
tumour patients.30 However, it is not known if it could
serve as an angiogenic target to increase vascularisa-
tion. In our cohort, when the ulcers entered the healing
phase, expression of TGFb3 and TGFBRIII were
unregulated and at this stage exogenous addition of
growth factors may be effective.
We anticipated that EGF and EGFR would be at the
forefront of epithelialisation in ischaemic ulcers
because of their central role in normal wound healing,
however, we found only minimal increases in EGFR
post-operatively. The reason for this difference in
ligand expression may reflect different functions of
growth factors in ischaemic epidermal cells and point
to the different wound healing processes following
revascularisation.
In summary, this study has revealed that the healing
that occurs following revascularisation of ischaemic
ulcers is by angiogenesis within the dermis of the ulcer
base. There is surprisingly little involvement of EGF inEur J Vasc Endovasc Surg Vol 31, May 2006
M. O. Murphy et al.522this process that is chiefly achieved by upregulation of
proangiogenic cytokines TGFb3 and PDGF and little
change in TGFb1. An increased understanding of the
processes that underpin successful healing in revascu-
larised arterial ulcers may well provide a therapeutic
target for improving ulcer healing rates following
bypass or provide alternate therapy for those unsui-
table for intervention.References
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